embecta is a global company focused on improving the health and well-being of people living with diabetes. Our history in insulin injection dates to 1924 and the development of the world's first specialized insulin syringe. Following a spinoff from Becton, Dickinson and Company in 2022, embecta become an independent, publicly-traded company and we are the world’s leading producer of insulin injection devices, manufacturing approximately 8 billion pen needles and syringes annually for an estimated 30 million people in 100+ countries. We work to advance the standard of care in insulin delivery through community partnerships, innovative technology and comprehensive care resources.